key: cord-0707523-4qcbwezv authors: Li, T.; Wang, L.; Wang, H.; Li, X.; Zhang, S.; Xu, Y.; Wei, W. title: Serum SARS-COV-2 Nucleocapsid Protein：A Sensitivity and Specificity Early Diagnostic Marker for SARS-COV-2 Infection date: 2020-05-26 journal: nan DOI: 10.1101/2020.05.24.20111849 sha: 0114eb4518e1da5699b9212f1dfc2d2b1c8f9186 doc_id: 707523 cord_uid: 4qcbwezv Objective: This study aimed to explore the diagnostic value of serum severe acute respiratory syndrome coronavirus 2 (SARSCoV2) nucleocapsid(N) protein assay in the early stage of SARSCOV2 infection. Method: Serum N protein in SARSCOV2 infected patients and non SARSCOV2 infected population was measured by enzyme-linked immunosorbent assay (ELISA) double antibody sandwich assay. Colloidal gold immunochromatography assay is used to detect serum N protein antibodies in the above population. Results: 50 cases of SARSCoV2 nucleic acid positive and SARSCoV2 antibody negative patients had a serum N protein positive rate of 76%, including 2% with a concentration of 10.00~49.99 pg / mL, 8% with a concentration of 50.00~99.99 pg / mL, 22% with a concentration of 100.00 ~299.99 pg/mL, and 44% with a concentration [≥]300.00 pg / mL. 37 samples of patients with serum SARSCoV2 antibody positive after infection had a serum SARSCoV2 N protein positive rate of 2.7%, of which 2.7% had the concentration of 10.00~49.99 pg / mL and 0% had the concentration of 50.00~99.99 pg / mL, 100.00 ~299.99 pg / mL, and [≥]300.00 pg / mL. Serum N protein test results of 633 non SARSCOV2 infected patients including pregnant women, other respiratory infections, and increased rheumatoid factor were all negative, having a serum N protein concentration less than 10.00 pg/mL, with a specificity of 100%. Using SPSS 19.0 to calculate the receiver operating characteristic curve, the area under the curve was 0.9756 (95% confidence interval 0.9485~1.000, p <0.0001), sensitivity and specificity were 92% (95% confidence interval 81.16% to 96.85%) and 96.84% (95% confidence interval 95.17% to 97.15%). The best CUTOFF value is 1.850 pg / mL. Conclusion: The measurement of SARSCOV2 serum N protein has a high diagnostic value for the infected patients before the antibody appears, and shortens the window period of serological diagnosis. The laboratory needs to establish an individual CUTOFF value according to purpose of the application. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.24.20111849 doi: medRxiv preprint As of May 16, 2020, there were more than 5.1 million severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and more than 333,000 deaths [1] , which posed a serious threat to the health and economic life of people around the world. With the joint efforts of scientists all over the world, a . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.24.20111849 doi: medRxiv preprint variety of diagnostic reagents have been developed to provide solid support for clinical diagnosis [2] [3] [4] [5] . At present, the diagnosis of SARS-COV-2 infection is mainly based on pharyngeal swab or sputum nucleic acid detection, and specific serum antibody detection is used as an auxiliary marker [6, 7] . Nucleic acid testing is greatly affected by specimen collection, transportation and other stages. There are times of inconsistent positive and negative results, and the overall positive rate is not high [8, 9] , which brings great confusion to the clinical diagnosis. The detection of specific antibodies against SARS-COV-2 in the serum will appear positive only about 7 days after infection or later in severe coronavirus disease 2019 (COVID-19) [7, 10] . It is difficult to detect early infections, which is not . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. Principle: Double antibody sandwich method is used to detect SARS-CoV-2 N protein in human serum. Results interpretation: The positive interpretation value (cutoff value) is 10.00 pg / mL. If the concentration of the specimen to be tested is less than 10.00 pg / mL, it is interpreted to be negative for SARS-COV-2 N protein. If the concentration of the specimen to be tested ≥ 10.00 pg / mL, it is interpreted as positive for SARS-COV-2 N protein. The SARS-COV-2 IgM / IgG antibody detection kit (colloidal gold method) (batch number SA200301) was developed by BIOHIT Healthcare (Hefei) Co., Ltd. Principle: Colloidal gold immunochromatography method is used to detect anti-SARS-CoV-2 IgM / IgG N protein antibody in human serum. Results interpretation: If the quality control line C developed color and the test line did not develop color, it is interpreted as negative. If the color of the quality control line C was developed, and the color of the test line was also developed, it is determined to be positive. If the quality control line C was not colored, the result is invalid and the sample needs to be re-tested. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. 2.3 Analysis of antibody titer and CT results of 4 patients whose N protein is consistently negative The serum antibody and CT results of 4 patients with consistent negative serum N protein results were tracked, the serum antibody was still negative or in low titer more than 9 days after the infected patients were admitted to the hospital. CT imaging showed that the inflammation of the lungs of the patients was mild or no obvious inflammation. Table3 Antibody titer and CT results of 4 patients whose N protein is consistently negative is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. 2.4 Specificity of SARS-COV-2 serum N protein assay at the CUTOFF value recommended by the manufacturer . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. Figure 1 ) When calculating the CUTOFF value using the ROC curve, the specificity of pregnancy population . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. Pulmonary inflammation is most common among SARS-CoV-2 infection, and it can also invade other tissues [11, 12] . Some patients have viremia. It was reported that SARS-CoV-2 RNA was detected in the blood among 15% of the 41 COVID-19 patients who were admitted to hospital for the first time in Wuhan [13] . The results of this study showed that 76.8% of patients diagnosed with SARS-CoV-2 infection were positive for N protein before the emergence of the N antibody (see Table 1 ). Further studies are needed to confirm whether the infected person has a higher incidence of viremia in the early stage or whether the over-expressed N protein of the lung virus spills into the blood. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.24.20111849 doi: medRxiv preprint Serum SARS-CoV-2 antibody test has been widely recognized as serological evidence for the diagnosis of COVID-19 [14] [15] [16] , but due to the lag in the development of antibodies, the clinical diagnosis "window period" is too long, and serum SARS-COV-2 antibody test is not suitable for the early diagnosis of SARS-CoV-2 infection [10, 15] . Our research results show that when the serum antibody is positive, the serum N protein positive rate is only 2.7%, and the overall serum N protein concentration value is low (see Table 2 ), suggesting that the detection of serum antibody and N protein has good complementary effects for the diagnosis of SARS-CoV-2 infection . The results in Table 3 show that 4 early serum N protein-negative patients had low antibody titers and CT showed that the lesions were mild or no obvious inflammation. Whether it is related to viral load in vivo remains to be further studied. The results in Table 1 , Table 4 and Table 5 showed that using the CUTOFF value recommended by the manufacturer, the specificity of serum N protein assay can reach 100%, but the sensitivity is only 76.8%. If the ROC curve is used to establish a personalized CUTOFF value, its specificity decreases to 96.84%, but its sensitivity increases to 92%. Therefore, we suggest that laboratories should select appropriate CUTOFF values according to the intended use. If you want to achieve higher diagnostic specificity, we recommend the use of CUTOFF values recommended by manufacturer. If you want to find as many infected people as possible and establish the basis for controlling the source of infection. It is recommended to select the CUTOFF value obtained from the ROC curve. The results of this study provide a laboratory basis for serum SARS-CoV-2 N protein detection for early diagnosis of infection. Compared with SARS-CoV-2 RNA detection from pharyngeal swab or sputum, serum SARS-CoV-2 N protein detection has obvious advantages in specimens collection and treatment. For example, N protein has better stability than RNA, which may effectively make up for missed diagnosis caused by RNA false negative results due to various reasons. Although the number of cases in this study was small, our results are extremely encouraging, which brings a new thought to the current incomplete diagnosis of SARS-CoV-2 infection. Combined detection of three markers: . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 4.2 According to the CUTOFF value recommended by the manufacturer, the specificity of SARS-COV-2 serum N protein detection is 100%, and the sensitivity is 76.8% before the antibody appearance. 4.3 Determining the CUTOFF value according to the ROC curve. The specificity of the SARS-COV-2 serum N protein detection was 96.84%, and the sensitivity was 92% before the antibody appearance. 4.4 It is recommended that each laboratory establishes its own CUTOFF value according to the purpose of the application. TL and LW had the idea for and designed the study and had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. HW, XL and SZ contributed to writing of the report. YX and WW contributed to the statistical analysis. All authors contributed to data acquisition, data analysis, or data interpretation, and reviewed and approved the final version. Disclaimer: The antibody screening, methodological selection and reagent production of this study were completed in the research and development department of Biohit Healthcare (Hefei) Co., Ltd. Methodological evaluation and performance verification were completed in the First Affiliated Hospital . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. Wuhan coronavirus (2019-ncov) global cases Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens Laboratory readiness and response for novel . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder -nCoV) in expert laboratories in 30 EU/EEA countries Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study New coronavirus pneumonia prevention and control program (trial version 7th ed) Clinical Features and Chest CT Manifestations of Coronavirus Disease Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) A pathological report of three COVID-19 cases by minimally invasive autopsies Ultrastructural Evidence for Direct Renal Infection with SARS-CoV-2 Clinical features of patients infected with A Peptide-based Magnetic Chemiluminescence Enzyme . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity The copyright holder for this preprint this version posted May 26, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.24.20111849 doi: medRxiv preprint